Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 3

Efficacy measurements of participants at week 12.

Characteristic	Treatment (n = 172)	Control (n = 174)	value
Percentage of patients with ≥50% reduction in frequency of headache, n (%)	123 (71.5)	21 (12.1)	<0.001
Frequency of headache attack, mean (SD)	2.81 ± 0.69	4.45 ± 1.03	<0.001
Days of headache attack, mean (SD)	4.99 ± 1.54	6.09 ± 1.48	<0.001
VAS, mean (SD)	4.81 ± 1.57	6.17 ± 1.65	<0.001
FSS, mean (SD)	23.34 ± 8.36	27.29 ± 7.62	<0.001
HAMD, mean (SD)	14.13 ± 5.55	16.78 ± 6.79	<0.001
MIDAS, mean (SD)	13.73 ± 4.29	17.52 ± 5.51	<0.001